Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AMT suspends Glybera and plans 50% job cuts in restructuring moves

This article was originally published in Scrip

Executive Summary

Following a negative opinion from the European Medicine's Agency's Committee for Medicinal Products for Human Use (CHMP) on its lead product, Glybera (alipogene tiparvovec) for the treatment of lipoprotein lipase deficiency (LPLD), Amsterdam Molecular Therapeutics has suspended its programme for the drug and announced a restructure that will reduce the number of full-time employees by a half.



Related Companies